Aortic valve replacement with Medtronic Freestyle bioprosthesis: 5-year results.
The Medtronic Freestyle aortic root bioprosthesis has been implanted in patients since August 1992. This study reviews clinical and echocardiographic results at midterm (5 years) after implantation. The Freestyle bioprosthesis was implanted in 1,100 patients in a 21-center Food and Drug Administration clinical trial from August 1992 to October 1998. The device was implanted (1) as a subcoronary valve replacement, (2) as a complete aortic root replacement (full-root), or (3) as a root inclusion. Patients were followed annually by clinical examination and echocardiography. There were 47 deaths early after operation (7.1%). There were 2,478 patient-years of follow-up during which there were 99 deaths or 4.0/pt.-yr. Before implantation, 73% of patients were in New York Heart Association functional class III or IV. After operation, 95% were in class I or II. Transvalvular gradient 4 years after operation was low (7.5+/-5.3 mm Hg) for all valve sizes (subcoronary implant). Small valves (19 and 21 mm) had mean gradients (10.2+/-3.0, 9.1+/-4.4 mm Hg). There was no or mild valve insufficiency in 98% of patients. Actuarial analysis at 5 years showed the rate for freedom from thromboembolism of 86% in subcoronary implant and 93% in full root replacement. Freedom from endocarditis was 98%. Freedom from reoperation for explant of the valve highest in patients having full root replacement (98%) and lower with root inclusion (94%). There were 20 bioprostheses explanted; 10 for endocarditis, 8 for technical reasons, and 2 for structural deterioration. The Medtronic Freestyle bioprosthesis (1) has excellent hemodynamic performance, (2) techniques for insertion that result in a competent valve, (3) low rates of thromboembolism and endocarditis, and (4) a rare rate of structural deterioration at 5 years.